Randomized, Double-Blind, Phase 3 Study Evaluating Tas-102 Plus Best Supportive Care (Bsc) Versus Placebo Plus Bsc In Patients With Metastatic Gastric Cancer Refractory To Standard Treatments

Disease (cancer type)

Gastric Cancer

Contact information

  • North Florida / Jacksonville: Astrid Corrales-Cruz (904) 427-1217

Patient Selection Criteria

Histologically confirmed, non-resectable, metastatic gastric adenocarcinoma including adenocarcinoma of the GE junction who have received at least 2 prior regimens (at least 1 cycle per regimen) for advanced disease, and were refractory to or unable to tolerate their last prior therapy.

Research sponsor


Reference ID#



  • Florida

Linked Physicians

To top